drugset / Trial / NCT04145375

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

NCT04145375

Phase 1/2 Enrolling by invitation 40 enrolled Zenith Epigenetics
NaSingle-groupOpen-labelTreatment

Summary

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Timeline

Start
2019-11-12
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ZEN-3694 Small molecule 120 mg
Background Enzalutamide Other / unclassified 160 mg